Therapeutic benefits of ACE inhibitors and other antihypertensive drugs in patients with type 2 diabetes

Diabetes Care

Volumn 23, Issue 7, 2000, Pages 888-892

  Pahor, Marco ^a,e   Psaty, Bruce M ^c   Alderman, Michael H ^d   Applegate, William B ^a   Williamson, Jeff D ^a   Furberg, Curt D ^b  

^a WAKE FOREST UNIVERSITY   (United States)

^b WAKE FOREST SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^d ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^e WAKE FOREST BAPTIST HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMLODIPINE; ATENOLOL; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CAPTOPRIL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; ENALAPRIL; FOSINOPRIL; NISOLDIPINE;

ADULT; AGED; ANTIHYPERTENSIVE ACTIVITY; ARTICLE; BLOOD PRESSURE REGULATION; DISEASE ASSOCIATION; DRUG EFFECT; ENZYME INHIBITION; FEMALE; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; OUTCOMES RESEARCH; RISK BENEFIT ANALYSIS; STROKE; TREATMENT OUTCOME;

EID: 0033911687     PISSN: 01495992     EISSN: None     Source Type: Journal    
DOI: 10.2337/diacare.23.7.888     Document Type: Article

References (22)

1. Curb JD, Pressel SL, Cutler JA, Savage PJ, Applegate WB, Black H, Camel G, Davis BR, Frost PH, Gonzalez N, Guthrie G, Oberman A, Rutan GH, Stamler J: Effect of diuretic-based antihypertensive treatment on cardiovascular disease risk in older diabetic patients with isolated systolic hypertension: Systolic Hypertension in the Elderly Program Cooperative Research Group. JAMA 276:1886-1892, 1996
2. Tuomilehto J, Rastenyte D, Birkenhager WH, Thijs L, Antikainen R, Bulpitt CJ, Fletcher AE, Forette F, Goldhaber A, Palatini P, Sarti C, Fagard R, Staessen JA: Effects of calcium-channel blockade in older patients with diabetes and systolic hypertension. N Engl J Med 340:677-684, 1999
3. Hansson L, Zanchetti A, Carruthers SG, Dahlof B, Elmfeldt D, Julius S, Menard J, Rahn KH, Wedel H, Westerling S: Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial: HOT Study Group. Lancet 351:1755-1762, 1998
4. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. BMJ 317:703-713, 1998
5. Pahor M, Psaty BM, Furberg CD: Treatment of hypertensive patients with diabetes. Lancet 351:689-690, 1998
6. Pahor M, Psaty BM, Furberg CD: New evidence on the prevention of cardiovascular events in hypertensive patients with type 2 diabetes. J Cardiovasc Pharmacol 32 (Suppl. 2): S18-S23, 1998
7. Estacio RO, Jeffers BW, Hiatt WR, Biggi SL, Gifford N, Schrier RW: The effect of nisoldipine as compared with enalapril on cardiovascular events in patients with non-insulin-dependent diabetes and hypertension. N Engl J Med 338:645-652, 1998
8. Hansson L, Lindholm LH, Niskanen L, Lanke J, Hedner T, Niklason A, Luomanmaki K, Dahlof B, de Faire U, Morlin C, Karlberg BE, Wester PO, Bjorck JE: Effect of angiotensin-converting-enzyme inhibition compared with conventional therapy on cardiovascular morbidity and mortality in hypertension: the Captopril Prevention Project (CAPPP) randomised trial. Lancet 353:611-616, 1999
9. Tatti P, Pahor M, Byington RP, DiMauro P, Guarisco R, Strollo G, Strollo F: Outcome results of the Fosinopril Versus Amlodipine Cardiovascular Events Randomized Trial in patients with hypertension and NIDDM. Diabetes Care 21:197-603, 1998
10. Efficacy of atenolol and captopril in reducing risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 39. BMJ 317:713-720, 1998
11. Hansson L, Lindholm LH, Ekbom T, Dahlof B, Lanke J, Schersten B, Wester PO, Hedner T, de Faire U: Randomised trial of old and new antihypertensive drugs in elderly patients: cardiovascular mortality and morbidity: the Swedish Trial in Old Patients With Hypertension-2 study. Lancet 354:1751-1756, 1999
12. Yusuf S, Peto R, Lewis J, Collins R, Sleight P: Beta blockade during and after myocardial infarction: an overview of the randomized trials. Prog Cardiovasc Dis 27:335-371, 1985
13. Cochran WG: Some methods lor strengthening the common chi-square tests. Biometrics 10:417-451, 1954
14. Nathan DM: Some answers, more controversy, from UKPDS: United Kingdom Prospective Diabetes Study. Lancet 352:832-833, 1998
15. Blumenfeld JD, Scaley JE, Mann SJ, Bragat A, Marion R, Pecker MS, Sotelo J, August P, Pickering TG, Laragh JH: Beta-adrenergic receptor blockade as a therapeutic approach for suppressing the reninangiotensin-aldosterone system in normotensive and hypertensive subjects. Am J Hypertens 12:451-459, 1999
16. Bridges AB, McLaren M, Belch JJ: A comparative study of captopril and enalapril on endothelial cell function in congestive heart failure patients. Angiology 46:811-817, 1995
17. Schindler R, Dinarello CA, Koch KM: Angiotensin-converting-enzyme inhibitors suppress synthesis of tumour necrosis factor and interleukin 1 by human peripheral blood mononuclear cells. Cytokine 7:526-533, 1995
18. Oshima S, Ogawa H, Mizuno Y, Yamashita S, Noda K, Saito T, Sumida H, Suefuji H, Kaikita K, Soejima H, Yasue H: The effects of the angiotensin-converting enzyme inhibitor imidapril on plasma plasminogen activator inhibitor activity in patients with acute myocardial infarction. Am Heart J 134:961-966, 1997
19. Vaughan DE, Rouleau JL, Ridker PM, Arnold JM, Menapace FJ, Pfeffer MA: Effects of ramipril on plasma fibrinolytic balance in patients with acute anterior myocardial infarction: HEART Study Investigators. Circulation 96:442-447, 1997
20. Heart Outcomes Prevention Evaluation Study Investigators: Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. N Engl Med 324:145-153, 2000
21. 1997 Joint National Committee: The Sixth Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Arch Intern Med 157:2413-2446, 1997
22. Davis BR, Cutler JA, Gordon DJ, Furberg CD, Wright JT, Cushman WC, Grimm RH, LaRosa J, Whelton PK, Perry HM, Alderman MH, Ford CE, Oparil S, Francis C, Proschan M, Pressel S, Black HR, Hawkins CM: Rationale and design for the Antihypertensive and Lipid Lowering Treatment To Prevent Heart Attack Trial (ALLHAT). Am J Hypertens 9:342-360, 1996